Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Adenosine receptors as therapeutic targets.

Jacobson KA, Gao ZG.

Nat Rev Drug Discov. 2006 Mar;5(3):247-64. Review.

2.

Introduction to adenosine receptors as therapeutic targets.

Jacobson KA.

Handb Exp Pharmacol. 2009;(193):1-24. doi: 10.1007/978-3-540-89615-9_1. Review.

3.

Adenosine and ischemic preconditioning.

Liang BT, Jacobson KA.

Curr Pharm Des. 1999 Dec;5(12):1029-41. Review.

4.

Adenosine receptors as promising therapeutic targets for drug development in chronic airway inflammation.

Polosa R, Holgate ST.

Curr Drug Targets. 2006 Jun;7(6):699-706. Review.

PMID:
16787172
5.

Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs.

Akkari R, Burbiel JC, Hockemeyer J, Müller CE.

Curr Top Med Chem. 2006;6(13):1375-99. Review.

PMID:
16918456
6.

Recent developments in adenosine receptor ligands and their potential as novel drugs.

Müller CE, Jacobson KA.

Biochim Biophys Acta. 2011 May;1808(5):1290-308. doi: 10.1016/j.bbamem.2010.12.017. Review.

7.

G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions.

Jacobson KA, Balasubramanian R, Deflorian F, Gao ZG.

Purinergic Signal. 2012 Sep;8(3):419-36. doi: 10.1007/s11302-012-9294-7. Review.

8.

Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review.

Rivera-Oliver M, Díaz-Ríos M.

Life Sci. 2014 Apr 17;101(1-2):1-9. doi: 10.1016/j.lfs.2014.01.083. Review.

9.

Adenosine receptors and their modulators.

Müller CE, Scior T.

Pharm Acta Helv. 1993 Sep;68(2):77-111. Review.

PMID:
8234392
10.

Newer targets for modulation of intraocular pressure: focus on adenosine receptor signaling pathways.

Agarwal R, Agarwal P.

Expert Opin Ther Targets. 2014 May;18(5):527-39. doi: 10.1517/14728222.2014.888416. Review.

PMID:
24579961
11.

International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE.

Pharmacol Rev. 2011 Mar;63(1):1-34. doi: 10.1124/pr.110.003285. Review.

12.

Medicinal chemistry of adenosine A3 receptor ligands.

Müller CE.

Curr Top Med Chem. 2003;3(4):445-62. Review.

PMID:
12570761
13.

Allosteric modulators for adenosine receptors: an alternative to the orthosteric ligands.

La Motta C, Sartini S, Morelli M, Taliani S, Da Settimo F.

Curr Top Med Chem. 2010;10(10):976-92. Review.

PMID:
20370657
14.

Adenosine receptor ligands: where are we, and where are we going?

Tuccinardi T, Martinelli A.

Curr Top Med Chem. 2010;10(10):941. No abstract available.

PMID:
20681944
15.

Adenosine receptor ligands: differences with acute versus chronic treatment.

Jacobson KA, von Lubitz DK, Daly JW, Fredholm BB.

Trends Pharmacol Sci. 1996 Mar;17(3):108-13. Review.

16.

Functional characterization of an endogenous Xenopus oocyte adenosine receptor.

Kobayashi T, Ikeda K, Kumanishi T.

Br J Pharmacol. 2002 Jan;135(2):313-22.

17.

Adenosine receptor desensitization and trafficking.

Mundell S, Kelly E.

Biochim Biophys Acta. 2011 May;1808(5):1319-28. doi: 10.1016/j.bbamem.2010.06.007. Review.

18.

Adenosine and adenosine receptors: Newer therapeutic perspective.

Manjunath S, Sakhare PM.

Indian J Pharmacol. 2009 Jun;41(3):97-105. doi: 10.4103/0253-7613.55202.

19.

Adenosine receptor ligands-recent developments part I. Agonists.

Muller CE.

Curr Med Chem. 2000 Dec;7(12):1269-88. Review.

PMID:
11032971
20.

Adenosine and protection from acute kidney injury.

Yap SC, Lee HT.

Curr Opin Nephrol Hypertens. 2012 Jan;21(1):24-32. doi: 10.1097/MNH.0b013e32834d2ec9. Review.

Items per page

Supplemental Content

Support Center